Natera (NASDAQ:NTRA) Director Herm Rosenman Sells 16,530 Shares

Natera, Inc. (NASDAQ:NTRA) Director Herm Rosenman sold 16,530 shares of the stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $250.00, for a total value of $4,132,500.00. Following the transaction, the director owned 4,250 shares in the company, valued at $1,062,500. This trade represents a 79.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Natera Price Performance

NASDAQ:NTRA opened at $261.91 on Friday. The company has a market capitalization of $37.51 billion, a price-to-earnings ratio of -160.68 and a beta of 1.56. The business has a 50 day moving average of $212.73 and a 200 day moving average of $215.87. Natera, Inc. has a 1-year low of $131.81 and a 1-year high of $271.47.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on NTRA shares. Sanford C. Bernstein started coverage on shares of Natera in a report on Friday. They set an “outperform” rating and a $310.00 target price on the stock. William Blair started coverage on shares of Natera in a research note on Tuesday, April 14th. They issued an “outperform” rating for the company. Morgan Stanley cut their price target on shares of Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a research report on Tuesday, March 3rd. Barclays reduced their price objective on Natera from $280.00 to $260.00 and set an “overweight” rating on the stock in a research note on Wednesday. Finally, Wall Street Zen downgraded Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Natera has a consensus rating of “Moderate Buy” and a consensus target price of $259.22.

Institutional Investors Weigh In On Natera

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. NewEdge Advisors LLC boosted its position in Natera by 3.4% during the 1st quarter. NewEdge Advisors LLC now owns 5,452 shares of the medical research company’s stock valued at $1,090,000 after buying an additional 179 shares during the period. Groupama Asset Managment increased its position in shares of Natera by 3.0% in the first quarter. Groupama Asset Managment now owns 95,061 shares of the medical research company’s stock valued at $19,011,000 after acquiring an additional 2,805 shares during the period. Oddo BHF Asset Management Sas purchased a new position in shares of Natera in the first quarter valued at about $6,410,000. Bull Harbor Capital LLC bought a new position in shares of Natera during the first quarter valued at about $1,543,000. Finally, Encore Global Management LP bought a new position in shares of Natera during the first quarter valued at about $1,200,000. 99.90% of the stock is currently owned by institutional investors.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.